Birdwatch Note
2023-01-16 19:31:39 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING
The overall incidence of COVID-19 mRNA vaccine–associated myocarditis was reported to be low, estimated as 0.3 to 5.0 cases per 100 000 vaccinated people. The incidence of myocarditis after SARS-CoV-2 infection is higher than after COVID-19 mRNA vaccination. https://jamanetwork.com/journals/jamapediatrics/fullarticle/2798866 https://www.cdc.gov/vaccines/covid-19/clinical-considerations/myocarditis.html
Written by E70FAE4DAD8D7443384AA849A1F8A5CB64505ED74C9FAEC5FB0AEC8462C340C3
Participant Details
Original Tweet
Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1615061281471402011
Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.
All Information
- ID - 1615069290146791436
- noteId - 1615069290146791436
- participantId - E70FAE4DAD8D7443384AA849A1F8A5CB64505ED74C9FAEC5FB0AEC8462C340C3
- noteAuthorParticipantId -
- createdAtMillis - 1673897499964
- tweetId - 1615061281471402011
- classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
- believable -
- harmful -
- validationDifficulty -
- misleadingOther - 0
- misleadingFactualError - 0
- misleadingManipulatedMedia - 0
- misleadingOutdatedInformation - 0
- misleadingMissingImportantContext - 1
- misleadingUnverifiedClaimAsFact - 0
- misleadingSatire - 0
- notMisleadingOther - 0
- notMisleadingFactuallyCorrect - 0
- notMisleadingOutdatedButNotWhenWritten - 0
- notMisleadingClearlySatire - 0
- notMisleadingPersonalOpinion - 0
- trustworthySources - 1
- summary
- The overall incidence of COVID-19 mRNA vaccine–associated myocarditis was reported to be low, estimated as 0.3 to 5.0 cases per 100 000 vaccinated people. The incidence of myocarditis after SARS-CoV-2 infection is higher than after COVID-19 mRNA vaccination. https://jamanetwork.com/journals/jamapediatrics/fullarticle/2798866 https://www.cdc.gov/vaccines/covid-19/clinical-considerations/myocarditis.html
Note Ratings
rated at | rated by | |
2023-01-16 19:54:28 -0600 | 01C9192BAFD574C9F68DAFD77D90D0258954277D021A709F2CB224779B9BB010 | Rating Details |
2023-01-17 04:37:47 -0600 | 020931EFDE8BED8FC4D9C607E381F58BDB9C4B82ED29075CBF6DEDF9BFFAA1B1 | Rating Details |
2023-01-16 14:44:41 -0600 | 07729C651F4CD42C14030CF6CC0D6099D767CFCB2DC305156D616DB514505E70 | Rating Details |
2023-01-16 18:40:29 -0600 | 094FEB9E3005DF49AFBA8C421AA6E9720FA97982BBB6770263AEA1BB036D8827 | Rating Details |
2023-01-16 15:32:05 -0600 | 0E3F6EB4AAF7233033251BACE0F0325D12DBDA5E1D67354D15807134017D9D96 | Rating Details |
2023-01-16 17:16:46 -0600 | 114D3959B7A1FAF013A9773725D3AC9653F490590C8B76CB7CE232B010DE900E | Rating Details |
2023-01-16 14:12:11 -0600 | 157949CA27417AE3FA2F206BF999B2137E57038260C7F6E46A9CE23270241D9A | Rating Details |
2023-01-16 18:05:46 -0600 | 17FB37075605AC14EB43D6C5F215C469EE87D044C7833F0AC6C813776C6ADCAE | Rating Details |
2023-01-16 21:07:33 -0600 | 185FDD2C8466D0FFB4CAFE72A8128D57A479EA5641B0BB317BB6A9D7E9743B13 | Rating Details |
2023-01-16 22:45:10 -0600 | 2C0C323337CADA4A449209AD8ECF2954421020C33C0FDAF5CAA4DD9CD50A4B60 | Rating Details |
2023-01-17 00:14:53 -0600 | 2FF394269BCEF49B71E6481EC02640680E3B728AFA4E52B6A7805E850BE3F189 | Rating Details |
2023-01-16 18:36:48 -0600 | 33EC0E8AE464AF97464945E210D61C07B9066E1CCD8F632E8D395F749ED89FA0 | Rating Details |
2023-01-16 13:35:45 -0600 | 3440E327FFC09396E77E3C806B2CE63500A27905ABDA4DA599C2EFB3935307B4 | Rating Details |
2023-01-16 18:52:40 -0600 | 45B8EF43682258D990F1C39DD9C1C131E030B7B116A1A874CAD37AED55F98C04 | Rating Details |
2023-01-16 23:03:52 -0600 | 49E68D0F137FBAADC316EEA761B671D21AE8B4A83C0804FF39800AB057A7583E | Rating Details |
2023-01-16 16:16:09 -0600 | 5EDC2B8BBEA2C25FBA40E8849AF6DD751A4AE52F674E4E2311C09F82909AD4F8 | Rating Details |
2023-01-16 20:01:25 -0600 | 5FD47DBD268BCED0B1472E8E3019C030A69DBEC0CDE9871FD564B3F72D3540C1 | Rating Details |
2023-01-16 15:19:53 -0600 | 7640BF10DEC76014715D6ADAC18E627AF02F2F4727C33862A234189728245F6C | Rating Details |
2023-01-16 20:22:43 -0600 | 7DAF7E766C91C4681BD9E35A65ED1244CD021FD7E551BF6AB85D6DF31D7EAC10 | Rating Details |
2023-01-16 18:33:00 -0600 | 7DD77FA934335AB7B4B777A968A8D56D68AA32E160053176586008F224AD5B99 | Rating Details |
2023-01-16 18:42:06 -0600 | 81BCEE69114361FA18C63808FCA69CA8496848B00DDADC71BBD24FEB72A2E524 | Rating Details |
2023-01-16 16:17:18 -0600 | 992932B0527A672C23AE61796C01072F45C13496756A150528BB74653898B6D4 | Rating Details |
2023-01-22 03:31:53 -0600 | B25D0204641493176A3A89929EA2BEDD51411476C8C57FFCEAF5877387ACA867 | Rating Details |
2023-01-16 18:35:07 -0600 | B3F75A38C7B7161100450BC24DB0D017C482FD679732EC692F27479971F660D4 | Rating Details |
2023-01-16 21:59:54 -0600 | BC4A347F32139628BA3DEE03965D242384327B338EBF4A42BB4A5DF40DE16164 | Rating Details |
2023-01-16 13:40:59 -0600 | C035D750AB8B340BF49F5276E70A2C3A8A302DFF0D6C9DA3A98A5C9AF54F1FBC | Rating Details |
2023-01-16 14:11:12 -0600 | C1F013D526C47286AB34C7124EEF321FBDE4FA50839797BCC5433EDCF67FC2F7 | Rating Details |
2023-01-16 20:24:31 -0600 | C966E0BA5803EDA2B9ADEA1A226B5D5FB13629349A2D9A920F01C5137F8AF13B | Rating Details |
2023-01-16 20:50:19 -0600 | CB6FA7DA75359C73181DFD438FD87E5707FB3DDD6D92C2D97AD2B3CDB54E321F | Rating Details |
2023-01-16 14:21:57 -0600 | D08095D829205610AFA96EE4745C814F88DFB5BE5B73E8468C45B69DA8E47F23 | Rating Details |
2023-01-16 21:45:06 -0600 | D69A8785D8EE58E2521238E78B541C1FD707DE422FD044F182564E619607000B | Rating Details |
2023-01-16 18:38:23 -0600 | F31EF85704A5DA7009FE991FC5953D12FB18A79D60A6202A6B8C669311E97254 | Rating Details |
2023-01-16 19:16:24 -0600 | F6677C15BDBBE389CA0CE103ED24D7FE925CE95D27A4DAA96FF5D02FD2D7E8D3 | Rating Details |
2023-01-16 14:44:41 -0600 | Rating Details | |
2023-01-16 20:24:31 -0600 | Rating Details | |
2023-01-16 23:03:52 -0600 | Rating Details | |
2023-01-16 18:52:40 -0600 | Rating Details | |
2023-01-16 18:36:48 -0600 | Rating Details | |
2023-01-16 19:16:24 -0600 | Rating Details | |
2023-01-16 18:05:46 -0600 | Rating Details | |
2023-01-16 19:54:28 -0600 | Rating Details | |
2023-01-16 21:45:06 -0600 | Rating Details | |
2023-01-17 00:14:53 -0600 | Rating Details | |
2023-01-22 03:31:53 -0600 | Rating Details | |
2023-01-16 18:35:07 -0600 | Rating Details | |
2023-01-16 20:01:25 -0600 | Rating Details | |
2023-01-16 16:17:18 -0600 | Rating Details | |
2023-01-16 17:16:46 -0600 | Rating Details | |
2023-01-16 14:11:12 -0600 | Rating Details | |
2023-01-17 04:37:47 -0600 | Rating Details | |
2023-01-16 18:33:00 -0600 | Rating Details | |
2023-01-16 20:22:43 -0600 | Rating Details | |
2023-01-16 18:42:06 -0600 | Rating Details | |
2023-01-16 14:12:11 -0600 | Rating Details | |
2023-01-16 21:59:54 -0600 | Rating Details | |
2023-01-16 15:32:05 -0600 | Rating Details | |
2023-01-16 13:35:45 -0600 | Rating Details | |
2023-01-16 22:45:10 -0600 | Rating Details | |
2023-01-16 15:19:53 -0600 | Rating Details | |
2023-01-16 18:38:23 -0600 | Rating Details | |
2023-01-16 16:16:09 -0600 | Rating Details | |
2023-01-16 18:40:29 -0600 | Rating Details | |
2023-01-16 13:40:59 -0600 | Rating Details | |
2023-01-16 21:07:33 -0600 | Rating Details | |
2023-01-16 20:50:19 -0600 | Rating Details | |
2023-01-16 14:21:57 -0600 | Rating Details |